Remember meForgot password?
    Log in with Twitter
| Press Release

Wired News – Myriad To Present Data From Study Of Myrisk(R) Hereditary Cancer Test At The 2018 Genitourinary Cancer Symposium

Stock Monitor: Forrester Research Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 09, 2018 / has just released a free research report on Myriad Genetics, Inc. (NASDAQ: MYGN). If you want access to this report all you need to do is sign up now by clicking the following link as the Company's latest news hit the wire. On February 07, 2018, the Company, which is a leading personalized medicine organization working towards transforming patient lives worldwide with pioneering molecular diagnostics, declared that it will present results from a large study of its MyRisk® Hereditary Cancer test during the poster presentation at the 2018 Genitourinary Cancer Symposium in San Francisco, California. Register today and get access to over 1000 Free Research Reports by joining our site below: is currently working on the research report for Forrester Research, Inc. (NASDAQ: FORR), which also belongs to the Services sector as the Company Myriad Genetics. Do not miss out and become a member today for free to access this upcoming report at: is focused on giving you timely information and the inside line on companies that matter to you. This morning, Myriad Genetics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

Robert Reid, M.D. from the Virginia Cancer Specialists, who also served as the lead investigator of this study, will present the data through a presentation titled ‘Inherited Germline Mutations in Men with Prostate Cancer'. He will present the data on Poster Board E4 on February 09, 2018, at 12:15 to 1:45 P.M. and 6:00 to 7:00 P.M. The study found that over 12% of men with prostate cancer had an inherited (hereditary) mutation in a cancer-causing gene.

Cancer of Prostate, Second Leading Cause of Cancer Death Among American Men

It is estimated that one in nine American men will have prostate cancer during his lifetime. At present, there are approximately 2.9 million American men living with the disease and an American man dies from prostate cancer every 18 minutes. That implies over 80 deaths per day and 29,430 per year. As per projections from The American Cancer Society, nearly 164,690 men will be diagnosed with prostate cancer in 2018.

About Myriad's myRisk® Hereditary Cancer Test

Myriad's myRisk Hereditary Cancer test uses numerous sophisticated technologies and proprietary algorithms to assess 28 clinically significant genes related to eight hereditary cancer sites including breast, colon, ovarian, endometrial, pancreatic, prostate, and gastric cancers and melanoma. It offers many distinct advantages to physicians over other commercial tests, such as unparalleled lab accuracy, industry leading variant classification, and remarkable customer service.

Details of the Study

This study intended to evaluate genetic testing leveraging Myriad's 28-gene myRisk Hereditary Cancer test in 1,162 men with a personal history of prostate cancer. Out of these 1,162 men, 64% had a history of prostate cancer, and 36% had a history of prostate cancer and at least one additional cancer. Test results validated that 12.1% of men with prostate cancer were positive for one or more hereditary cancer mutations in the genes tested. In fact, the positive rate was much higher for men with prostate cancer plus one other cancer, i.e. 14.7%.

Also, it must be noted that inherited mutations were found in genes with a well-known prostate cancer risk (i.e., BRCA2) and also in genes historically associated with other cancer types like breast and colon. The findings prove that hereditary cancer testing in men with prostate cancer could be very helpful in medical management decision making to reduce overall cancer risk.

Need For Genetic Testing In Men Diagnosed With Prostate Cancer

This study was one of the largest studies of hereditary cancer risk assessment ever conducted in prostate cancer. It highlighted that almost the same proportion of men with prostate cancer carry hereditary cancer-causing mutations as women with breast cancer. The study findings provide a strong reason for expanding the use of genetic testing in men diagnosed with prostate cancer, in-line with the existing professional medical guidelines.

This hereditary cancer testing can facilitate informed treatment decision making for these men. It would help them decide whether or not to pursue active surveillance and increased screening for secondary cancers. Besides, it will assist them in selecting the right treatment with PARP inhibitors or other medicines in the future. Also, when they know that they carry an inherited mutation, they can also encourage their family members to get tested and find out if they are at increased risk for cancer. Such efforts can help them prevent future cancers.

National Comprehensive Cancer Network Also Supports Hereditary Cancer Risk Assessment

The National Comprehensive Cancer Network, the American Urological Association (AUA), and an academic consensus panel also reaffirmed the need for hereditary cancer risk assessment for patients with prostate cancer, who are at high risk due to metastatic disease or high grade cancer with a family history of BRCA associated cancers including breast, ovarian, pancreatic, or prostate cancer.

In fact, the AUA suggests that patients with localized prostate cancer, who are at higher risk for developing metastatic castration-resistant prostate cancer, could have a higher incidence of germline DNA repair mutations than expected from published reports. This presence of germline DNA repair gene mutations has significant implications for prostate cancer patients in terms of general cancer screening and possible future prostate cancer treatment decisions. The presence of germline DNA repair mutations is also relevant for the patient's first-degree family members as it increases cancer risk and screening implications.

Stock Performance Snapshot

February 08, 2018 - At Thursday's closing bell, Myriad Genetics' stock declined 3.58%, ending the trading session at $32.62.

Volume traded for the day: 1.02 million shares, which was above the 3-month average volume of 782.55 thousand shares.

Stock performance in the last three-month – up 9.10%; previous six-month period – up 16.58%; and past twelve-month period – up 97.46%

After yesterday's close, Myriad Genetics' market cap was at $2.35 billion.

Price to Earnings (P/E) ratio was at 21.98.

The stock is part of the Services sector, categorized under the Research Services industry.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:


Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Latest News
Top News